Familial dysfibrinogenemia: Difference between revisions

Jump to navigation Jump to search
Michael Maddaleni (talk | contribs)
No edit summary
Prashanthsaddala (talk | contribs)
No edit summary
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{SI}}
{{SI}}
{{CMG}}
{{CMG}}
{{SK}} Dysfibrinogenemia, familial


==Overview==
==Overview==
Line 14: Line 16:
*'''Wiesbaden''' is a major defect, there is aggregation of fibrin monomers, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is both bleeding and thrombosis.
*'''Wiesbaden''' is a major defect, there is aggregation of fibrin monomers, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is both bleeding and thrombosis.


 
==References==
{{reflist|2}}





Latest revision as of 19:39, 21 September 2012

WikiDoc Resources for Familial dysfibrinogenemia

Articles

Most recent articles on Familial dysfibrinogenemia

Most cited articles on Familial dysfibrinogenemia

Review articles on Familial dysfibrinogenemia

Articles on Familial dysfibrinogenemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Familial dysfibrinogenemia

Images of Familial dysfibrinogenemia

Photos of Familial dysfibrinogenemia

Podcasts & MP3s on Familial dysfibrinogenemia

Videos on Familial dysfibrinogenemia

Evidence Based Medicine

Cochrane Collaboration on Familial dysfibrinogenemia

Bandolier on Familial dysfibrinogenemia

TRIP on Familial dysfibrinogenemia

Clinical Trials

Ongoing Trials on Familial dysfibrinogenemia at Clinical Trials.gov

Trial results on Familial dysfibrinogenemia

Clinical Trials on Familial dysfibrinogenemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Familial dysfibrinogenemia

NICE Guidance on Familial dysfibrinogenemia

NHS PRODIGY Guidance

FDA on Familial dysfibrinogenemia

CDC on Familial dysfibrinogenemia

Books

Books on Familial dysfibrinogenemia

News

Familial dysfibrinogenemia in the news

Be alerted to news on Familial dysfibrinogenemia

News trends on Familial dysfibrinogenemia

Commentary

Blogs on Familial dysfibrinogenemia

Definitions

Definitions of Familial dysfibrinogenemia

Patient Resources / Community

Patient resources on Familial dysfibrinogenemia

Discussion groups on Familial dysfibrinogenemia

Patient Handouts on Familial dysfibrinogenemia

Directions to Hospitals Treating Familial dysfibrinogenemia

Risk calculators and risk factors for Familial dysfibrinogenemia

Healthcare Provider Resources

Symptoms of Familial dysfibrinogenemia

Causes & Risk Factors for Familial dysfibrinogenemia

Diagnostic studies for Familial dysfibrinogenemia

Treatment of Familial dysfibrinogenemia

Continuing Medical Education (CME)

CME Programs on Familial dysfibrinogenemia

International

Familial dysfibrinogenemia en Espanol

Familial dysfibrinogenemia en Francais

Business

Familial dysfibrinogenemia in the Marketplace

Patents on Familial dysfibrinogenemia

Experimental / Informatics

List of terms related to Familial dysfibrinogenemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Dysfibrinogenemia, familial

Overview

The dysfibrinogenemias are a group of autosomal dominant disorders of qualitatively abnormal fibrinogens. There are various different fibrinogen abnormalities, each named after the place where it was discovered. Each dysfibrinogenemia is associated with slightly different effects on the thrombin time and on normal clotting.

Classification

Some dysfibrinogenemias cause abnormal bleeding or even thrombosis, while others have no affect on either bleeding or thrombosis. Some examples are;

  • Amsterdam is a major defect, characterized by aggregation of fibrin monomers, prolonged thrombin time, and an inhibitory effect on normal clotting - but it is asymptomatic.
  • Detroit is a major defect, there is fibrinopeptide release, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is abnormal bleeding.
  • Wiesbaden is a major defect, there is aggregation of fibrin monomers, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is both bleeding and thrombosis.

References

Template:WH Template:WikiDoc Sources